Capricor signs binding term sheet with Nippon Shinyaku for European deramiocel rights; $15M equity + $20M upfront

CAPRICOR THERAPEUTICS, INC.

Nippon Shinyaku to commercialize deramiocel in EU, UK and other European countries; Capricor receives double-digit revenue share.
Up to $715M in milestone payments plus $20M upfront upon definitive agreement (expected Q4 2024); combined milestones now ~$1.5B.
Private placement of 2.8M shares at $5.36 (20% premium to 60-day VWAP) raises ~$15M; proceeds extend cash runway into 2026.
Capricor to develop and manufacture deramiocel; meeting with EMA planned to discuss European expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.